- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 13, Issue 35, 2007
Current Pharmaceutical Design - Volume 13, Issue 35, 2007
Volume 13, Issue 35, 2007
-
-
Editorial [Hot Topic: Angiogenesis Agents (Executive Editor: Cezary Marcinkiewicz)]
More LessAngiogenesis, a process of growing new vasculature from pre-existing vessels, is a phenomenon that is the focus of investigation of many laboratories. The pharmacological research targeting this process is related into two aspects, inhibition of pathological angiogenesis such as in cancer development, and therapeutic angiogenesis promoting a vessel growth during several cardiovascular disorders. Highly advance Read More
-
-
-
Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Authors: Sith Sathornsumetee and Jeremy N. RichMalignant glioma represents one of the most lethal and angiogenic cancers. Angiogenesis is a fundamental process of blood vessel growth that is a hallmark of cancer. Although several molecular mechanisms contribute to tumor angiogenesis in gliomas, the vascular endothelial growth factor (VEGF) pathway appears particularly important and has been a prominent therapeutic target in cancer treatment. Several preclinical stu Read More
-
-
-
CD36-TSP-HRGP Interactions in the Regulation of Angiogenesis
Authors: Roy L. Silverstein and Maria FebbraioThrombospondin (TSP)-1 and -2 are potent inhibitors of angiogenesis in vivo and of microvascular endothelial cell responses to angiogenic factors in vitro. The anti-angiogenic activity of thrombospondins is contained in a structural domain known as the TSP type I repeat or TSR. TSR domains are present in many other proteins, several of which have also been shown to have anti-angiogenic activity and a peptide-mimetic drug Read More
-
-
-
The Role of Annexin II in Angiogenesis and Tumor Progression: A Potential Therapeutic Target
Authors: Mahesh C. Sharma and Meena SharmaIt is well established that human tumors overproduce plasmin a serine protease that is known to promote angiogenesis, tumor growth and metastasis. However, the mechanism by which endothelial or tumor cells regulate the proteolytic activity of plasmin is not well understood. Cell surface receptors regulate activation of plasminogen to plasmin and its proteolytic activity. Annexin II is one of the well studied receptor Read More
-
-
-
Identification of Novel Drug Targets for Angiostatic Cancer Therapy; It Takes Two to Tango
Authors: Victor L.J.L. Thijssen, Judy R. van Beijnum, Kevin H. Mayo and Arjan W. GriffioenThe development of novel treatment strategies for therapy of angiogenesis-dependent diseases requires identification of specific tumor endothelial cell markers to which therapeutic agents can be targeted. This can be achieved by random or targeted approaches. Random approaches are based on genomic screening to identify differences between normal and activated endothelium. Targeted approaches utilize known angi Read More
-
-
-
Modulation of Angiogenesis for Cancer Prevention: Strategies Based On Antioxidants and Copper Deficiency
Authors: Gazala N. Khan and Sofia D. MerajverAlthough anti- angiogenesis strategies have generated much enthusiasm for therapeutic applications, it is still unknown whether they would be feasible for prevention. The possibility of interfering very early in tumor progression by modulating the cancer angiogenic switch is appealing. In this chapter, we review progress with in vitro and in vivo models that show that anti-angiogenic interventions may be amenable to long- Read More
-
-
-
Nitric Oxide-Dependent Neovascularization Role in the Lower Extremity Disease
Authors: Monica G. Arellano Mendoza, Hilda V. Robles, Eunice Romo, Amelia Rios and Bruno EscalantePeripheral arterial occlusive disease (PAD) describes vascular disorders associated with ischemia and PAD affects about 8 million people in the United States. Moreover, PAD's prevalence can increase dramatically if cardiovascular disease is present. In healthy individuals reducing blood flow through the lower extremity is followed by a physiological process to limit ischemia in the distal tissue. This process is called revasculariz Read More
-
-
-
Modified Fibrin Hydrogel Matrices: Both, 3D-Scaffolds and Local and Controlled Release Systems to Stimulate Angiogenesis
By Heike HallSufficient blood perfusion is essential for all tissues to guarantee nutrient- and gas exchange. As many diseases are induced by the reduction of blood perfusion such that these tissues gradually loose their ability to function properly, therapeutic angiogenesis aims to increase blood flow in ischemic tissues by stimulating the patient's endogenous capacity to develop new blood vessels. These studies include application of ang Read More
-
-
-
Type I Collagen and Collagen Mimetics as Angiogenesis Promoting Superpolymers
Authors: T. Twardowski, A. Fertala, J. P.R.O. Orgel and J. D. San AntonioAngiogenesis, the development of blood vessels from the pre-existing vasculature, is a key component of embryogenesis and tissue regeneration. Angiogenesis also drives pathologies such as tumor growth and metastasis, and hemangioma development in newborns. On the other hand, promotion of angiogenesis is needed in tissues with vascular insufficiencies, and in bioengineering, to endow tissue substitutes with appr Read More
-
-
-
Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
More LessStatins are pluripotent agents exhibiting multiple non-lipid-lowering actions. Besides their established role in the management of hypercholesterolemia, statins may also have beneficial actions in other pathological conditions, namely: a) osteoporosis and osteoporosis- related bone fractures, b) cancer, c) solid organ transplantation, d) cerebrovascular events (transient ischemic attack and stroke episodes), e) v Read More
-
-
-
Weight Loss in Older Persons: New Therapeutic Approaches
More LessThere is now a large body of evidence that weight loss in older persons not only increases mortality, but also increases the incidence of hip fracture, functional deterioration and institutionalization. Weight loss is a central component of frailty. There is evidence that it is not only muscle, but also fat loss that leads to these deleterious effects. The reasons why fat loss can be harmful in older persons are reviewed. There ar Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
- Issue 36
- Issue 35
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 3
- Issue 2
- Issue 1
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
